Research overview
What is Thymosin Beta-4 (TB-4)?
Thymosin beta-4 is a 43-residue peptide involved in actin-binding and studied in tissue-repair systems. TB-500 is a short derived fragment with separate metabolite data. Data for one cannot be assigned to the other.
What has research examined?
A randomized placebo-controlled phase 2 trial of 72 participants with moderate-to-severe dry eye studied a topical Thymosin beta-4 ophthalmic solution. Its two primary endpoints, ocular discomfort and inferior corneal staining, did not significantly differ at the specified visit, though selected secondary endpoints favored the study solution.
Secondary topical-eye signals cannot establish generalized wound repair or injectable safety. No amount, preparation, or use is suggested.
Research references
- Thymosin beta-4 ophthalmic solution: randomized phase 2 dry-eye trialClinical Ophthalmology
- TB-500 fragment/metabolite experimental data (not full-length TB-4)Journal of Chromatography B
Calculation boundary
The cited clinical trial tested a defined ophthalmic solution, not a generic injected vial. Full-length TB-4 and short TB-500 fragments differ; a syringe chart cannot bridge those formulations.